Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zealand Pharma A/S ZLDPY

Healthcare Biotechnology

Recent & Breaking News (GREY:ZLDPY)

Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide

GlobeNewswire October 12, 2017

Zealand Pharma A/S commences initial public offering of American Depositary Shares in the United States

GlobeNewswire August 1, 2017

Zealand reports royalty revenue for the second quarter of 2017

GlobeNewswire July 31, 2017

Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes

GlobeNewswire July 3, 2017

Zealand to regain control of elsiglutide

GlobeNewswire June 12, 2017

New analysis shows Soliqua® 100/33 lowered HbA1c by more than 2% in patients with screening levels greater than 9%

GlobeNewswire June 10, 2017

Dasiglucagon (pINN) presentation at the 77th Scientific Sessions of the American Diabetes Association (ADA) indicate use for treatment of severe hypoglycemia

GlobeNewswire June 10, 2017

Zealand to present at two international healthcare investor conferences in June 2017

GlobeNewswire June 2, 2017

Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system

GlobeNewswire May 23, 2017

CORRECTION: Zealand reports results for the first three months of 2017 (unaudited)

GlobeNewswire May 17, 2017

Zealand reports results for the first three months of 2017 (unaudited)

GlobeNewswire May 17, 2017

Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim

GlobeNewswire May 11, 2017

Zealand reports Q1 2017 royalty revenue

GlobeNewswire April 28, 2017

Zealand announces full-year results in line with guidance and releases its Annual Report for 2016

GlobeNewswire March 15, 2017

Zealand hosts conference call on March 15 at 4 pm CET to present 2016 full-year results

GlobeNewswire March 13, 2017

Zealand reports Q4 2016 Lyxumia® royalty revenue

GlobeNewswire February 8, 2017

Notice of the date of Zealand's Annual General Meeting 2017 and of deadline for proposals for the agenda

GlobeNewswire February 7, 2017

Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome

GlobeNewswire February 6, 2017

EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand

GlobeNewswire January 17, 2017

Zealand reports that Sanofi announces Soliqua(TM) 100/33 now available in the U.S

GlobeNewswire January 4, 2017